We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Synthetic Nucleic Acids Restore Normal Frataxin Levels in Patient-Derived Friedreich's Ataxia Cells

By LabMedica International staff writers
Posted on 02 Mar 2016
Neurological disease researchers have used synthetic nucleic acid polymers to block the defective FXN gene segment and restore normal levels of frataxin in cells derived from patients with Freidreich's ataxia.

Friedreich's ataxia is an autosomal recessive disorder that occurs when the FXN gene contains amplified repeats of the GAA (guanine-adenine-adenine) nucleotide sequence. More...
The FXN gene encodes the protein frataxin, but GAA repeat expansion causes frataxin levels to be reduced. Frataxin is an iron-binding protein responsible for forming iron-sulfur clusters. One result of frataxin deficiency is mitochondrial iron overload which can cause damage to many proteins, which can result in a variety of symptoms that include loss of muscle control, fatigue, vision or hearing impairment, slurred speech, and serious heart conditions.

Investigators at the University of Texas Southwestern Medical Center (Dallas, USA) developed synthetic nucleic acids to block the effects of GAA expansion and restore normal frataxin levels.

In a paper published in the February 4, 2016, online edition of the journal Nature Communications the investigators reported that by introducing anti-GAA duplex RNAs or single-stranded locked nucleic acids into patient-derived cells, they were able to increase frataxin expression to levels similar to analogous wild-type cells. These results were considered to be significant, since synthetic nucleic acids that target GAA repeats could lead to the development of compounds for restoring curative frataxin levels. More broadly, they demonstrated a new strategy for upregulating gene expression.

"The problem arises because of a mutation within the frataxin gene (FXN) that does not code for protein. In this case, the mutation causes the synthesis of a longer piece of RNA. This longer sequence binds the DNA and gums up the works, blocking RNA production needed to produce the frataxin protein," said senior author Dr. David Corey, professor of pharmacology and biochemistry at the University of Texas Southwestern Medical Center. "The synthetic DNA or RNA prevents the mutant sequence from bending back and blocking the frataxin gene. This action activates the frataxin gene, which then makes frataxin RNA and protein at normal levels. In addition, our approach is selective for targeting the frataxin gene FXN and does not affect other genes."

Related Links:

University of Texas Southwestern Medical Center



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
HPV Molecular Test
BD Onclarity HPV Assay
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Graphical abstract (Pola, I., Akinyemi, T., Tan, K. et al. Nature Communications(2026). https://doi.org/10.1038/s41467-026-74971-4)

Blood Biomarker Study Reveals Population-Specific Differences in Alzheimer’s Disease

Blood-based biomarkers are emerging as tools for detecting Alzheimer’s disease–related changes without relying on advanced brain imaging or cerebrospinal fluid (CSF) analysis. However, much of the foundational... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.